News | Stereotactic Body Radiation Therapy (SBRT) | April 23, 2021

Study Finds Stereotactic Body Radiotherapy Safe for Treating Patients with Multiple Metastases

A phase 1 clinical trial led by investigators at the University of Chicago Medicine testing the effects of stereotactic body radiotherapy for treating multiple metastases has determined that treatments used for single tumors can also be safely used for treating patients with multiple metastases.

Image courtesy of Accuray

April 23, 2021 — A phase 1 clinical trial led by investigators at the University of Chicago Medicine testing the effects of stereotactic body radiotherapy for treating multiple metastases has determined that treatments used for single tumors can also be safely used for treating patients with multiple metastases. The study was run through NRG Oncology and sponsored by the National Cancer Institute. The results were published on April 22 in JAMA Oncology. 

Cancer is traditionally treated with a combined approach, with clinicians using surgery, chemotherapy and radiation therapy to kill and remove cancerous tumors. Systemic treatments such as chemotherapy often are not enough to stop the cancer’s growth.

Stereotactic body radiation therapy (SBRT) is a type of radiation therapy that uses precisely targeted beams of very high doses of radiation to destroy tumors. The higher doses are more effective at killing cancer cells than traditional radiation therapy, while the careful targeting of tumors reduces damage to noncancerous tissue.

This approach has been used successfully to treat small, early stage tumors, but until now, it was not clear if such high doses of radiation would be safe in patients with multiple tumors due to metastatic cancer. Because SBRT uses multiple, high-intensity radiation beams, physicians have to be especially careful in locating tumors and targeting the radiation beams to maximize benefits and minimize risks — a challenge that Steven Chmura, M.D., Ph.D., likened to trying to “cross the beams” in the “Ghostbusters” movie. 

“Part of the difficulty is working out the logistics for testing this approach in patients across multiple institutions,” said Chmura, Professor of Radiation and Cellular Oncology at UChicago Medicine. “We’ve thought for a long time that you could treat three or four metastases at the same time, but it’s very technically complicated to do so. But before we could test this in something like a large, phase 3 clinical trial, we had to prove that we could get multiple institutions together and come up with a ‘cook book’ for how to do this right, ensuring that treatment was the same across the board. This was really like seven phase 1 clinical trials rolled into one.” 

A phase 1 clinical trial, led by Chmura, set out to test the safety of such an approach. In a trial of 39 patients who had breast, prostate or non-small cell lung cancer with at least three metastases or two metastases in close proximity, the investigators determined that there were no treatment-related deaths and that the approach was safe enough to begin phase 2/3 clinical trials in a larger group of patients.

“At the end of the trial, the primary endpoint of six-month dose limiting toxicity was 0%,” Chmura said. “This shows us that treating three or four sites of metastases throughout the body with these high-ablative doses of radiotherapy is safe.”

Radiation therapy is not without risks. While the study found that no patients experienced side effects severe enough to call off the study, several adverse events were linked to the treatment, including gastric ulcers, broken bones and bone pain, and pneumonitis. In many cases during the four-year trial, these side effects appeared months to years following treatment, highlighting the importance of maintaining long-term follow-up contact with these patients. Overall, however, none of these treatments or side effects led to increased risk of death. 

“People have been saying for years that if we used SBRT in patients with multiple, limited metastases, we could potentially cure more patients,” said Chmura. “But we needed to conduct these large-scale, phase 2/3 clinical trials to prove that. And before we can do those large trials, we had to set up the infrastructure. The greatest challenge was having a whole team of people come together and figure out how we could define the doses and manage the real-time quality assurance to make sure every single patient had the best treatment possible.”

With this collaborative infrastructure in place, the investigators have launched additional trials to test the efficacy of stereotactic body radiation therapy for treating patients with multiple metastases. The group is currently enrolling patients in a phase 2/3 trial for using SBRT for the treatment of metastatic breast cancer, with the goal of treating up to 450 people.

The study, “Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases,” was supported by NRG Oncology (UG1CA189867, U10CA180868, U10CA180822) and the National Cancer Institute (U24CA180803). Additional authors include Hania Al-Hallaq and Yasmin Hasan of the University of Chicago Medicine, Kathryn Winter and Jennifer Moughan of NRG Oncology, Clifford Robinson of Washington University, Thomas Pisansky and Sean Park of the Mayo Clinic, Virginia Borges of the University of Colorado-Anschutz Medical Center, Martha Matuszak of the University of Michigan, Sun Yi of the University of Arizona Medical Center, Jose Bazan and Julia White of the Ohio State University, Philip Wong of the Centre Hospitalier de L’Universite de Montréal, Harold Yoon of the Heartland Cancer Research National Cancer Institute, Janet Horton and Joseph Salama of the Duke University Medical Center, Gregory Gan of the New Mexico Minority Underserved National Cancer Institute Community Oncology Research Program,  Michael Milano of the University of Rochester, and Elin Ruth Sigurdson of the Fox Chase Cancer Center.

For more information: www.uchicagomedicine.org

Related Content

The 15-ton compact accelerator is lifted into the David C. Pratt Cancer Center at Mercy St. Louis. (Photo: Business Wire)

The 15-ton compact accelerator is lifted into the David C. Pratt Cancer Center at Mercy St. Louis. (Photo: Business Wire)

News | Radiation Oncology | July 21, 2021
July 23, 2021 — Mevion Medical Systems announced that it has delivered the 15-ton compact accelerator to...
ASTRO just issued the following statement in response to the Radiation Oncology Model update in yesterday's HOPPS proposed rule, which compounds significant and detrimental cuts to the cancer care specialty in the proposed 2022 MPFS

Getty Images

News | Radiation Therapy | July 20, 2021
July 20, 2021 — In response to consecutive weeks of proposed...
Artificial intelligence-powered diagnostic tool spots asymptomatic prostate cancer in seconds

(L-R) Associate Professor Peter Brotchie (St Vincent's), Dr Ruwan Tennakoon (RMIT), Professor John Thangarajah (RMIT), Dr Mark Page (St Vincent's). Image courtesy of St Vincent's Hospital Melbourne

News | Prostate Cancer | July 19, 2021
July 19, 2021 — Prostate cancer is the most diagnosed
Ramon Alfredo Siochi, Ph.D. — the director of medical physics at WVU — led a task group to help ensure the accuracy of data that dictates a cancer patient's radiation therapy.

Ramon Alfredo Siochi, director of medical physics at West Virginia University. Image courtesy of WVU Photo/Aira Burkhart

News | Radiation Oncology | July 15, 2021
July 15, 2021 — Just as helicopter traffic reporters use their "bird's eye view" to route drivers around roadblocks s
 The numbers of cancer screening tests rebounded sharply in the last quarter of 2020, following a dramatic decline in the first months of the COVID-19 pandemic, at one large hospital system in the Northeastern United States. These findings were released in a study published in Cancer Cell. The research also found an increase in racial and socioeconomic disparities among users of some screening tests during the pandemic.

Getty Images

News | Radiation Oncology | July 12, 2021
July 12, 2021 — The numbers of...
To help enhance the images and information provided to clinicians for radiation oncology treatment planning, GE Healthcare will integrate Spectronic Medical’s AI-based software with its industry leading AIR Recon DL technology
News | Artificial Intelligence | July 09, 2021
July 9, 2021 — GE Healthcare announced the integration of S...
American Society for Radiation Oncology (ASTRO) to host in-person Annual Meeting in Chicago, October 24-27

Getty Images

News | ASTRO | July 08, 2021
July 8, 2021 — Registration opens today for the American Society for Radiation Oncology's (...

Image courtesy of RaySearch

Feature | Treatment Planning | July 07, 2021 | Information provided by Grand View Research